These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 15284261

  • 1. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
    Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R.
    J Clin Oncol; 2004 Aug 01; 22(15):3104-12. PubMed ID: 15284261
    [Abstract] [Full Text] [Related]

  • 2. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 3. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS.
    Cancer; 2005 Jan 01; 103(1):76-84. PubMed ID: 15540247
    [Abstract] [Full Text] [Related]

  • 4. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2006 Jun 01; 15(6):1137-41. PubMed ID: 16775172
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):421-7. PubMed ID: 11352850
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.
    Endocr Relat Cancer; 2006 Jun 01; 13(2):583-92. PubMed ID: 16728584
    [Abstract] [Full Text] [Related]

  • 7. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
    Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ.
    Gastroenterology; 2005 Aug 01; 129(2):464-75. PubMed ID: 16083703
    [Abstract] [Full Text] [Related]

  • 8. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 9. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.
    Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P.
    Cancer Epidemiol Biomarkers Prev; 2005 Jan 01; 14(1):48-52. PubMed ID: 15668475
    [Abstract] [Full Text] [Related]

  • 10. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
    Serrano D, Baglietto L, Johansson H, Mariette F, Torrisi R, Onetto M, Paganuzzi M, Decensi A.
    Clin Cancer Res; 2005 Mar 01; 11(5):2083-8. PubMed ID: 15756035
    [Abstract] [Full Text] [Related]

  • 11. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2005 May 01; 14(5):1270-3. PubMed ID: 15894684
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF, Hsing AW.
    Cancer Res; 2001 Jun 01; 61(11):4333-6. PubMed ID: 11389055
    [Abstract] [Full Text] [Related]

  • 13. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
    Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2002 Nov 01; 11(11):1413-8. PubMed ID: 12433720
    [Abstract] [Full Text] [Related]

  • 14. Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway.
    Vatten LJ, Holly JM, Gunnell D, Tretli S.
    Cancer Epidemiol Biomarkers Prev; 2008 Aug 01; 17(8):2097-100. PubMed ID: 18708402
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
    Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE.
    Cancer Epidemiol Biomarkers Prev; 2007 Aug 01; 16(8):1691-5. PubMed ID: 17684148
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
    Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS.
    Cancer Epidemiol Biomarkers Prev; 2006 Dec 01; 15(12):2461-6. PubMed ID: 17164371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F.
    Clin Cancer Res; 2003 Oct 15; 9(13):4722-9. PubMed ID: 14581342
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.